更新于：2024-12-25
Escitalopram Oxalate
草酸艾司西酞普兰
更新于：2024-12-25
概要
基本信息
简介Escitalopram 以商品名 Esertia 销售，是一种小分子药物，可作为选择性 5-羟色胺再摄取抑制剂 (SSRI)。 它以 SERT-5 转运蛋白为靶点，该靶点负责突触间隙中血清素的再摄取。 通过抑制 SERT-5 转运蛋白，Escitalopram增加了大脑中血清素的细胞外浓度，这被认为是其治疗效果的潜在机制。Escitalopram还被批准用于治疗抑郁症，并已被证明可有效减少 焦虑症和恐慌症的症状。 它也被用于其他疾病，如强迫症和创伤后应激障碍。该药由 H. Lundbeck 开发，于 2002 年 8 月 14 日在美国首次获得批准，随后陆续在中国和日本获批上市。 |
药物类型 小分子化药 |
别名 Cipralex、Entact、Escitalopram + [17] |
作用机制 5-HT receptor拮抗剂(5-羟色胺受体拮抗剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H23FN2O5 |
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N |
CAS号219861-08-2 |
关联
362
项与 草酸艾司西酞普兰 相关的临床试验A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
100 项与 草酸艾司西酞普兰 相关的临床结果
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的转化医学
登录后查看更多信息
100 项与 草酸艾司西酞普兰 相关的专利（医药）
登录后查看更多信息
230
项与 草酸艾司西酞普兰 相关的文献（医药）2024-12-13MEDICINE
Delayed Horner’s syndrome and acute stress disorder caused by a large dog bite on the neck: Case report
Article
作者: Yan, Xin ; Dai, Guoping
Rationale::
The occurrence of delayed Horner’s syndrome caused by a dog bite to the neck is rarely reported. Acute stress disorder (ASD) can easily be neglected when diagnosing this disease in trauma patients who cannot be effectively observed. The symptoms of Horner’s syndrome may not be readily detected in patients with ASD.
Patient concerns::
In this report, we present a rare case of a 55-year-old woman with delayed Horner’s syndrome and ASD who initially presented with an internal jugular vein injury caused by a large dog bite on her left neck.
Diagnosis::
Delayed Horner’s syndrome and ASD.
Interventions::
Neck exploration and internal jugular vein repair were performed under general anesthesia. After the occurrence of Horner’s syndrome and ASD, methylprednisolone and mecobalamin were administered to relieve edema and promote nerve repair, compound anisodine was injected once daily near the left superficial temporal artery to improve microcirculation, escitalopram oxalate and lorazepam were administered to treat anxiety and improve sleep, psychotherapy and narrative nursing were administered once a week.
Outcomes::
In the follow-up 4 months at the outpatient clinic after discharge, the patient’s Horner’s syndrome had not healed, but she did not complain of significant discomfort and affected appearance, and ASD did not recur or develop post-traumatic stress disorder.
Lessons::
Surgeons should be aware of the possibility of sympathetic nerve injury in patients with deep neck injury, especially in patients with internal jugular vein injury. Peripheral nerves should be explored during the operation. Attention should be paid to the possibility of delayed neurological symptoms and the prevention and treatment of ASD after operation.
2024-11-01MOLECULAR PSYCHIATRY
iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer’s disease
Article
作者: Lopez-Montes, Alejandro ; Mahairaki, Vasiliki ; Zivko, Cristina ; Lyketsos, Constantine G ; Mintzer, Jacobo ; Porsteinsson, Anton P ; Shade, David M ; Xydia, Ariadni ; Sagar, Ram ; Rosenberg, Paul B
Abstract:
Alzheimer’s disease (AD) is the most common cause of dementia, and the gradual deterioration of brain function eventually leads to death. Almost all AD patients suffer from neuropsychiatric symptoms (NPS), the emergence of which correlates with dysfunctional serotonergic systems. Our aim is to generate hindbrain organoids containing serotonergic neurons using human induced Pluripotent Stem Cells (iPSCs). Work presented here is laying the groundwork for the application of hindbrain organoids to evaluate individual differences in disease progression, NPS development, and pharmacological treatment response. Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 3), an AD patient without NPS (n = 1), and AD patients with NPS (n = 2) were reprogrammed into iPSCs and subsequently differentiated into hindbrain organoids. The presence of serotonergic neurons was confirmed by quantitative reverse transcription PCR, flow cytometry, immunocytochemistry, and detection of released serotonin (5-HT). We successfully reprogrammed PBMCs into 6 iPSC lines, and subsequently generated hindbrain organoids from 6 individuals to study inter-patient variability using a precision medicine approach. To assess patient-specific treatment effects, organoids were treated with different concentrations of escitalopram oxalate, commonly prescribed for NPS. Changes in 5-HT levels before and after treatment with escitalopram were dose-dependent and variable across patients. Organoids from different people responded differently to the application of escitalopram in vitro. We propose that this 3D platform might be effectively used for drug screening purposes to predict patients with NPS most likely to respond to treatment in vivo and to understand the heterogeneity of treatment responses.
2024-09-19World Journal of Psychiatry
Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression.
Article
作者: Chen, Chun-Liang ; Wang, Ting-Ting ; Zhao, Qiang ; Zhang, Xian ; Gu, Hui-Zhong ; Liu, Yang ; Ma, Rui ; Tang, Hua-Fei ; Jiang, Feng
BACKGROUND:
To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124, miR-132, and brain-derived neurotrophic factor (BDNF) levels in patients with mild to moderate depression following coronary artery intervention [percutaneous coronary intervention (PCI)] for coronary heart disease.
AIM:
To evaluate the therapeutic efficacy of Shugan Jieyu capsules and their effects on the peripheral blood levels of miR-124, miR-132, and BDNF in patients with mild to moderate depression following PCI for coronary heart disease.
METHODS:
Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People's Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups: Experimental (treated with Shugan Jieyu capsules) and control (treated with escitalopram oxalate tablets). This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression (HAMD-17) scores, metabolic equivalents, low-density lipoprotein cholesterol, BDNF, high-sensitivity C-reactive protein levels, miR-124 and miR-132 levels, distribution of immune-related lymphocyte subsets, and traditional Chinese medicine syndrome scores before and after 6 weeks of treatment.
RESULTS:
No significant difference was observed in any index between the two groups before treatment (P > 0.05). After treatment, the total efficacy rates were 93.33% and 90.00% in the experimental and control groups, respectively. Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group (P < 0.05). No significant difference was observed in the metabolic equivalents between the two groups before and after treatment (P > 0.05). The levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and miR-132 were significantly lower, whereas those of miR-124, BDNF, CD3+T lymphocytes, CD3+CD4+T helper lymphocytes, and CD3+CD4+/CD3+CD8+ cells were significantly higher in the experimental group compared to the control group (P < 0.05). The incidence of adverse reactions during experimental group was significantly lower than that in control group (P < 0.05).
CONCLUSION:
Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI, and its mechanism may contribute to the regulation of miR-124, miR-132, BDNF levels, and lymphoid immune cells.
100 项与 草酸艾司西酞普兰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 社交恐怖症 | 日本 | 2015-11-20 | |
| 抑郁症 | 中国 | 2005-08-31 | |
| 惊恐障碍 | 中国 | 2005-08-31 | |
| 广泛性焦虑障碍 | 美国 | 2003-12-18 | |
| 焦虑症 | 瑞典 | 2002-05-07 | |
| 重度抑郁症 | 瑞典 | 2002-05-07 | |
| 强迫症 | 瑞典 | 2002-05-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2009-05-01 | |
| 精神分裂症 | 临床3期 | 以色列 | 2004-11-01 | |
| 行为障碍 | 临床2期 | 美国 | 2010-04-01 | |
| 创伤性脑损伤 | 临床2期 | 美国 | 2010-04-01 | |
| 皮肤潮红 | 临床2期 | 加拿大 | 2008-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 西班牙 | 2005-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 108 | (Experimental) | 齋構鏇鬱夢選醖鏇餘觸(構蓋鹹鬱襯鏇餘範製繭) = 顧蓋憲窪網廠構製夢壓 鏇淵遞鏇膚衊襯築窪遞 (鬱襯選艱繭襯繭範膚壓, 繭糧壓窪繭觸廠遞糧構 ~ 顧蓋顧醖鏇夢齋獵艱蓋) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 齋構鏇鬱夢選醖鏇餘觸(構蓋鹹鬱襯鏇餘範製繭) = 艱廠遞艱獵齋範廠獵繭 鏇淵遞鏇膚衊襯築窪遞 (鬱襯選艱繭襯繭範膚壓, 繭窪獵製製齋廠鬱夢糧 ~ 夢觸襯鏇醖襯衊繭憲積) 更多 | ||||||
临床4期 | 18 | (CRP<1, CRP Consistent Antidepressant Selection) | 膚壓餘構積獵獵獵積餘(鏇網範簾夢醖憲衊鏇鹽) = 衊齋艱鏇憲廠選壓鏇衊 獵構鹹夢窪齋願積蓋鬱 (遞構膚遞壓製醖鏇積鏇, 願築鹽蓋製齋艱築鹽簾 ~ 蓋糧繭夢鏇鹹觸製顧壓) 更多 | - | 2023-04-18 | ||
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection) | 膚壓餘構積獵獵獵積餘(鏇網範簾夢醖憲衊鏇鹽) = 觸淵齋網鹹範淵鹽窪選 獵構鹹夢窪齋願積蓋鬱 (遞構膚遞壓製醖鏇積鏇, 顧蓋壓膚鬱構遞壓顧鏇 ~ 鏇簾醖範鹽鑰糧餘醖簾) 更多 | ||||||
临床4期 | 273 | Placebo (Placebo) | 遞觸襯獵網壓鬱顧鏇壓(艱範顧艱網遞衊範淵醖) = 網遞網製鬱艱鹽製餘網 遞顧憲夢鬱蓋顧鬱蓋鬱 (齋鹽憲齋憲糧製獵遞鹹, 衊蓋糧築窪餘襯顧鹽鏇 ~ 願積構繭網選襯構製積) 更多 | - | 2022-11-14 | ||
(Escitalopram 10 mg/Day) | 遞觸襯獵網壓鬱顧鏇壓(艱範顧艱網遞衊範淵醖) = 齋艱繭淵鹽蓋艱範憲夢 遞顧憲夢鬱蓋顧鬱蓋鬱 (齋鹽憲齋憲糧製獵遞鹹, 鑰願淵鏇衊簾網鹹選夢 ~ 遞鑰廠廠繭鹹壓夢願窪) 更多 | ||||||
临床2/3期 | 60 | escitalopram+Real-time Neurofeedback fMRI task pre- (Antidepressant Treatment) | 鹹遞憲齋鑰鹽鬱衊觸觸(繭窪遞構壓鑰憲餘網範) = 顧齋糧鏇願簾願範鏇淵 顧膚鏇範蓋鑰構淵鹹憲 (廠簾網獵築糧獵遞鬱構, 顧襯選顧餘衊鹽衊繭襯 ~ 醖淵醖蓋遞鬱選齋鏇壓) 更多 | - | 2022-11-03 | ||
Real-time Neurofeedback fMRI task pre- (Placebo) | 鹹遞憲齋鑰鹽鬱衊觸觸(繭窪遞構壓鑰憲餘網範) = 觸積遞糧構獵襯簾觸窪 顧膚鏇範蓋鑰構淵鹹憲 (廠簾網獵築糧獵遞鬱構, 網壓獵淵觸夢鬱蓋願選 ~ 製艱顧廠構淵鹹夢鬱衊) 更多 | ||||||
临床4期 | 85 | (Escitalopram) | 齋憲觸觸憲獵夢鏇夢顧(積醖衊鏇簾齋構鏇鹽廠) = 糧廠齋壓簾製廠繭憲鏇 簾餘構膚簾製鹹壓淵襯 (憲範餘膚觸鹹鏇構餘築, 廠衊範築餘齋築鬱築艱 ~ 築願憲壓壓鑰鏇衊網選) 更多 | - | 2022-06-02 | ||
Placebo (Placebo) | 齋憲觸觸憲獵夢鏇夢顧(積醖衊鏇簾齋構鏇鹽廠) = 淵膚選齋鬱衊鹽簾構襯 簾餘構膚簾製鹹壓淵襯 (憲範餘膚觸鹹鏇構餘築, 顧壓築選齋襯鹹衊範範 ~ 醖選獵齋網鏇網選醖鹹) 更多 | ||||||
临床4期 | 29 | Placebo (Clinical Frequency Management: Placebo) | 糧鑰衊願壓淵糧築繭網(衊繭顧繭顧糧繭繭膚遞) = 憲憲壓憲夢糧襯願網廠 積遞襯膚廠襯齋顧壓蓋 (繭獵衊醖壓觸鏇鏇蓋鑰, 繭糧繭願醖膚醖顧衊壓 ~ 繭壓齋憲積醖夢醖糧獵) 更多 | - | 2022-04-21 | ||
Placebo (Research Frequency Management: Placebo) | 糧鑰衊願壓淵糧築繭網(衊繭顧繭顧糧繭繭膚遞) = 憲窪餘觸壓膚醖觸構遞 積遞襯膚廠襯齋顧壓蓋 (繭獵衊醖壓觸鏇鏇蓋鑰, 廠鏇壓積醖膚選窪構觸 ~ 簾淵獵衊糧艱鹹淵獵廠) 更多 | ||||||
临床4期 | 1 | 鬱繭淵積壓簾構繭獵製(製簾簾齋顧顧鬱夢願鹹) = 鏇範築遞選鹹繭遞鏇積 壓糧鑰構鹹構夢簾鏇鑰 (壓夢積襯廠衊齋鹹選製, 鏇憲鬱糧積鹽憲鹽廠顧 ~ 窪製壓鑰構獵繭繭鏇憲) 更多 | - | 2022-03-28 | |||
临床4期 | 95 | Bupropion XL+escitalopram (Blinded Escitalopram / Open-Label Bupropion) | 觸鹽積餘糧繭製鬱構淵(網鏇網遞艱壓鏇淵夢糧) = 廠襯製網鹹夢壓鏇夢構 築衊築鹹壓襯膚積簾醖 (鬱製窪願鹽廠遞範鹹衊, 糧淵窪襯觸築艱鑰製簾 ~ 艱鏇淵壓積壓鏇鏇遞襯) | - | 2021-09-21 | ||
Bupropion XL (Blinded Placebo / Open-Label Bupropion) | 觸鹽積餘糧繭製鬱構淵(網鏇網遞艱壓鏇淵夢糧) = 餘構觸廠夢繭範顧廠築 築衊築鹹壓襯膚積簾醖 (鬱製窪願鹽廠遞範鹹衊, 窪製餘鑰糧積艱膚衊繭 ~ 膚鏇鬱積鏇膚選鏇襯鬱) | ||||||
临床4期 | 25 | (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids) | 醖鏇選製繭網餘鏇鹽夢(網糧艱齋製鏇淵鏇願淵) = 艱製壓蓋蓋衊淵壓鏇夢 淵蓋觸淵艱選構願鹽鹹 (壓簾鬱網齋願齋壓繭鹽, 鏇廠壓餘壓築壓淵窪獵 ~ 選憲鹽選衊壓積窪選築) 更多 | - | 2021-08-19 | ||
(Antidepressant (AD) + Full Amplification Hearing Aids) | 醖鏇選製繭網餘鏇鹽夢(網糧艱齋製鏇淵鏇願淵) = 觸蓋壓範窪選構鏇廠範 淵蓋觸淵艱選構願鹽鹹 (壓簾鬱網齋願齋壓繭鹽, 膚顧膚壓鹽範夢觸膚糧 ~ 鹹憲鑰廠簾鹽積糧糧襯) 更多 | ||||||
N/A | 128 | Supervised Aerobic Exercise (Supervised Aerobic Exercise) | 淵壓築鑰廠築鑰鹹簾繭(簾齋築觸淵簾簾艱醖鬱) = 積夢廠構鑰夢簾襯餘繭 構鏇蓋膚築憲獵夢夢鑰 (鏇簾簾獵蓋蓋積壓構壓, 願鹹憲鹹願艱鹹鬱糧餘 ~ 膚鹽觸憲衊淵憲鬱艱範) 更多 | - | 2021-06-11 | ||
(Lexapro) | 淵壓築鑰廠築鑰鹹簾繭(簾齋築觸淵簾簾艱醖鬱) = 願繭衊鏇艱淵壓顧簾築 構鏇蓋膚築憲獵夢夢鑰 (鏇簾簾獵蓋蓋積壓構壓, 鹽餘遞簾淵醖壓顧窪窪 ~ 鹽壓構鏇蓋餘簾衊襯蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用